These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16810558)

  • 1. Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.
    Gueorguieva I; Aarons L; Rowland M
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):571-94. PubMed ID: 16810558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM.
    Langdon G; Gueorguieva I; Aarons L; Karlsson M
    Eur J Clin Pharmacol; 2007 May; 63(5):485-98. PubMed ID: 17345074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fuzzy simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam.
    Gueorguieva II; Nestorov IA; Rowland M
    J Pharmacokinet Pharmacodyn; 2004 Jun; 31(3):185-213. PubMed ID: 15518244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based pharmacokinetic modelling.
    Ando H; Izawa S; Hori W; Nakagawa I
    Theor Biol Med Model; 2008 Aug; 5():19. PubMed ID: 18687151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study.
    Gueorguieva I; Nestorov IA; Rowland M
    J Pharmacokinet Pharmacodyn; 2006 Feb; 33(1):1-27. PubMed ID: 16369700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim.
    Tsiros P; Bois FY; Dokoumetzidis A; Tsiliki G; Sarimveis H
    J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):173-192. PubMed ID: 30949914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics.
    Wendling T; Dumitras S; Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):639-57. PubMed ID: 26231433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.
    Yang S; Roger J
    Pharm Stat; 2010; 9(4):313-30. PubMed ID: 20043295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models.
    Yau E; Gertz M; Ogungbenro K; Aarons L; Olivares-Morales A
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):346-359. PubMed ID: 36647756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian approach for PK/PD modeling with PD data below limit of quantification.
    Zhou H; Hartford A; Tsai K
    J Biopharm Stat; 2012; 22(6):1220-43. PubMed ID: 23075019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fuzzy physiologically based pharmacokinetic modeling framework to predict drug disposition in humans.
    Seng KY; Vicini P; Nestorov IA
    Conf Proc IEEE Eng Med Biol Soc; 2006; Suppl():6485-8. PubMed ID: 17959432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-drug interaction prediction: a Bayesian meta-analysis approach.
    Li L; Yu M; Chin R; Lucksiri A; Flockhart DA; Hall SD
    Stat Med; 2007 Sep; 26(20):3700-21. PubMed ID: 17357990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.
    Wendling T; Tsamandouras N; Dumitras S; Pigeolet E; Ogungbenro K; Aarons L
    AAPS J; 2016 Jan; 18(1):196-209. PubMed ID: 26538125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.
    Park ES; Symanski E; Han D; Spiegelman C
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):51-113. PubMed ID: 26333239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models.
    Rosner GL; Müller P
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):209-33. PubMed ID: 9408860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    Biopharm Drug Dispos; 2014 Nov; 35(8):485-99. PubMed ID: 25044007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.